ATHJF News Alert Antisense Therap Ltd (ATHJF) 0.1268 09/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Antisense Therap Ltd (ATHJF) 0.1268 $ATHJF

ATL1103 Phase II Trial - Successful Efficacy Results
PR Newswire - Tue Sep 02, 6:19PM CDT
Antisense Therapeutics Limited ("ANP" or "the Company" is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The Phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I (sIGF-I) levels of 26% from baseline (P<0.0001) at week 14 (one week past the last dose) at the 400mg per week dose tested.

ATL1103 Acromegaly Phase II Trial Dosing Completed
PR Newswire - Tue Jul 29, 7:00AM CDT
Antisense Therapeutics Limited ("ANP" is pleased to report that dosing of all 26 patients in the Phase II trial of ATL1103 for the potentially life-threatening growth disorder, acromegaly has now been completed. There were no patient withdrawals or reports of any serious adverse events related to dosing with ATL1103. Patients will continue to be monitored for a period of two months after their last dose of ATL1103.

ATL1102 for MS - Toxicology Study Main Findings
PR Newswire - Tue Apr 01, 8:45AM CDT
Antisense Therapeutics Limited ("ANP" or the "Company" is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose). The Company believes that the preclinical and clinical experience to date with ATL1102 should allow dosing in future trials at or above the 1.5 mg/kg/dose level.

ATL1103 Acromegaly Phase II Trial Recruitment Completed
PR Newswire - Fri Mar 21, 9:00AM CDT
Antisense Therapeutics Limited ("ANP" is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.

ATL1102 for Stem Cell Mobilisation Trial Commencement
PR Newswire - Mon Mar 17, 6:20PM CDT
Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept trial of ATL1102, the Company's second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells (CD34+) into the blood when dosed alone and in combination with an existing therapy (Granulocyte Colony Stimulating Factor (G-CSF)). The randomised, open label study of ATL1102 dosed over 5 days (given on day 1, 3 and 5) in 10 healthy volunteers is being conducted by leading Clinical Research Organisation, Nucleus Network at its clinical trial unit at the Alfred Hospital, Melbourne, Victoria. (The Study "Protocol Synopsis" following this announcement provides further information).

Antisense Therapeutics Selected to Present at Biotech Showcase(TM) 2014
PR Newswire - Tue Jan 07, 4:49PM CST
Antisense Therapeutics Limited ("ANP" or "the Company" is pleased to advise that it has been selected to present at the Biotech Showcase 2014 conference to be held January 13-15, 2014, at The Parc 55 Wyndham Hotel in San Francisco, CA. This is a significant opportunity for ANP to present to and engage with distinguished US-based investors, prospective partners, and key industry leaders, and in particular discuss the successful progress of the company's Phase II acromegaly trial for ATL1103.

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6d8jw/hematopoietic) has announced the addition of the "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013" report to their offering. 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation. Scope - A snapshot of the global therapeutic scenario for Hematopoietic Stem Cell Transplantation. - A review of the Hematopoietic Stem Cell Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Hospira, Inc. Athersys, Inc. GlaxoSmithKline plc BioLineRx, Ltd. Celldex Therapeutics, Inc. Antisense Therapeutics Limited Actinium Pharmaceuticals, Inc. Pharmalink AB Polyphor Ltd. Kiadis Pharma B.V. Bellicum Pharmaceuticals, Inc. TaiGen Biotechnology Co., Ltd. TikoMed AB For more information visit http://www.researchandmarkets.com/research/n6...atopoietic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ANP to present at and attend major US investment, partnering and industry conferences
PR Newswire - Wed Aug 28, 6:30AM CDT
Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been invited to present at two major investment and partnering focused conferences in the US, and will also attend an industry seminar on orphan drugs and rare diseases as the Company steps up its planning on its drug ATL1103 for acromegaly.

Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in Development of Antisense Therapeutics
Business Wire - Fri Aug 09, 8:30AM CDT
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that a scientific assay has confirmed that its lead product candidate BP-100-1.01 (Liposomal Grb-2) inhibits the disease-causing target protein in patients with blood cancers. The assay was applied to patient samples taken from Bio-Path's Phase I clinical trial which is evaluating Liposomal Grb-2 in blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). This discovery is a significant milestone in the development of Bio-Path's liposomal delivery technology and the specific data from this testing is planned to be reviewed at the Annual Society of Hematology (ASH) meeting in December by Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center).




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 87

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 158

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
NCPDP Elevates J.W. Hill to President & COO Role

Updated Category News Views 46

Plotting the Course for NCPDP's Future Today's shakeup at the NCPDP has got the sector's ears perked. For those who don't speak in acronym soup all day—NCPDP stands for National Council for Prescription Drug Programs. They're the brains behind many crucial healthcare standards, improving information flow around meds, supplies, and services. Now, they're taking bold...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 73

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 104

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 103

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 173

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 102

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Lululemon Faces Class Action: Navigating Investor Impact

Updated Category News Views 65

Lululemon's Legal Storm: Understanding the Background If you thought the yoga gear game was all about stretch and flexibility, Lululemon Athletica, Inc (NASDAQ: LULU) just yanked us back to reality. The company finds itself in a legal tangle with its shareholders following a dismal performance report and a subsequent lawsuit. This situation has unfolded like a second-rate...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Organizations: RockDove Solutions on Crisis Communication

Updated Category News Views 111

Understanding the Importance of Crisis Communication Plans In today's fast-paced world, effective crisis communication is more critical than ever for businesses. Surprisingly, fewer than half of U.S. companies have formal crisis communication strategies in place. This statistic highlights a significant gap in business continuity planning, where communication often...

Continue Reading
Hafnia Limited Reports Strong Earnings for Q3 2024 Period

Updated Category News Views 83

Hafnia Limited Reports Strong Earnings for Q3 2024 Period Hafnia Limited (“Hafnia” or “the Company”, OSE ticker code: “HAFNI”, NYSE ticker code: “HAFN”), a premier product tanker company with an extensive and modern fleet exceeding 130 vessels, has recently reported promising financial results for the three and nine months ended September 30, 2024. Key...

Continue Reading
Recent Shareholding Changes at Irish Continental Group PLC

Updated Category News Views 138

Understanding Director and PDMR Shareholding Notifications In the world of corporate governance, transparency plays a crucial role in maintaining trust, particularly when it comes to senior management and directors. Recent notifications reveal key transactions involving persons discharging managerial responsibilities (PDMRs) at Irish Continental Group plc. Overview of...

Continue Reading
Experience the Summer Vibes at Coastal Mississippi Events

Updated Category News Views 220

Summer Events in Coastal Mississippi Come Play Coastal all summer long with seafood feasts, fireworks, car shows, and more! Ready to turn up the fun this summer? Coastal Mississippi is bringing a thrilling lineup of unforgettable events, all set against the backdrop of 62 miles of beautiful shoreline. From fresh seafood to electrifying fireworks, sensational car shows,...

Continue Reading
GUNNAR Optiks and 2K Games Unveil Exciting New Glasses

Updated Category News Views 197

GUNNAR Optiks Partners with 2K Games for New Glasses GUNNAR Optiks, a frontrunner in combating digital eye strain and a pioneer in blue light blocking eyewear, has teamed up with 2K Games to introduce an exciting new collection inspired by the much-anticipated Borderlands 4. This striking collection unveils its first eyewear style, aptly named the Ripper, marking the...

Continue Reading